Location Directory

Clinical trials in Atlanta, Georgia

This page shows live ClinicalTrials.gov search results for Atlanta, Georgia, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

13066

Shown on this page

Current sort

Institutions in Atlanta

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Emory University (Winship Cancer Institute)

Live official records

Open in full search

Conditions: Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease
Interventions: Local laboratory testing, Local Lab Tests; Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: Up to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 14 more

Conditions: Aortic Valve Stenosis
Interventions: Medtronic Transcatheter Aortic Valve Replacement Systems, Surgical Aortic Valve Replacement (SAVR); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 2,223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 61
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 53 more

Conditions: Crohn's Disease
Interventions: IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 87
States / cities: Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 72 more

Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 92
States / cities: Irvine, California • Los Angeles, California • Newport Beach, California + 72 more

Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Digital Rectal Examination, High Resolution Anoscopy, Magnetic Resonance Imaging, Nivolumab, Patient Observation, Proctoscopy, Sigmoidoscopy, X-Ray Imaging; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 887
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 568 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: IVA337, Placebo; Drug
Lead sponsor: Inventiva Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 194
States / cities: Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more

Conditions: Juvenile Myoclonic Epilepsy
Interventions: JZP926 capsule, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 10 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more

Conditions: Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography and Computed Tomography Scan, Lumbar Puncture, Multigated Acquisition Scan, Tovorafenib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 180 Days to 22 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 108
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 85 more

Conditions: Mild Cognitive Impairment, Alzheimer Disease
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions: ANG003 Dose A, ANG003 Dose B, Creon; Drug
Lead sponsor: Anagram Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 28
States / cities: Long Beach, California • Los Angeles, California • Denver, Colorado + 24 more

Conditions: Viral Lung Infection and Acute Respiratory Failure
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more

Conditions: Chronic Graft-versus-host-disease
Interventions: INCA034176, Placebo, Corticosteroids; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 32 more

Clinical trials in Atlanta, Georgia

Filter and sort this location

Institutions in Atlanta

Live official records

Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant.

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia

Phase 2 Study to Assess the Safety and Efficacy of ANG003

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease